2,2′,4,4′,5,5′-Hexachlorobiphenyl as a 2,3,7,8-tetrachlorodibenzo-p-dioxin antagonist in C57BL6J mice

Biegel, Lisa B.; Harris, Mark Anglin; Davis, D.; Rosengren, Rhonda J.; Safe, L.; Safe, Stephen

doi:10.1016/0041-008x(89)90261-5

Cited by 102 publications

(39 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…With respect to nonadditive effects between TCDD and PCB 153 on CYPlAI induction in rodents, it was observed that synergism prevailed at the lower dose levels, while antagonism dominated at higher dose levels (95). Mechanistically, this antagonism can be explained by the fact that less potent congeners still have Ah receptor binding affinities and therefore are effective competitors for binding the site (195,209). This reduces the probability of the more toxic dioxinlike compounds to bind to the Ah receptor.…”

Section: Review Of Tefs Approach For Deriving Tefsmentioning

confidence: 95%

“…From the available experimental data, it appears that antagonism is the most commonly reported nonadditive effect between individual dioxinlike compounds and complex mixtures (195,(208)(209)(210)(211)(212). However, it should be noted that the occurrence of either antagonism or synergism is ratio and dose dependent.…”

Section: Review Of Tefs Approach For Deriving Tefsmentioning

confidence: 99%

“…Recendy, these nonadditive interactions of PCB on dioxinlike effects have been reviewed (193). In summary, the following antagonistic effects ofnondioxinlike PCBs were described: induction of EROD activity in chick embryo hepatocytes (194), splenic PFC response to sheep erythrocytes in mice (195), splenic PFC response to trinitrophenyl-lipopolysaccharide in mice (196), serum IgM units in mice (91), mouse fetal deft palate (110,195), and chick embryo malformations and edema and liver lesions (197). The apparent antagonism by PCB 153 of the TCDD-induced immunosupression is due to the enhanced immune response induced by PCB 153 (198).…”

Section: Review Of Tefs Approach For Deriving Tefsmentioning

confidence: 99%

See 2 more Smart Citations

Toxic equivalency factors (TEFs) for PCBs, PCDDs, PCDFs for humans and wildlife.

Berg

Birnbaum

Bosveld

et al. 1998

Environ Health Perspect

2,935

975

View full text Add to dashboard Cite

Section: Review Of Tefs Approach For Deriving Tefsmentioning

confidence: 95%

Section: Review Of Tefs Approach For Deriving Tefsmentioning

confidence: 99%

Section: Review Of Tefs Approach For Deriving Tefsmentioning

confidence: 99%

See 1 more Smart Citation

Toxic equivalency factors (TEFs) for PCBs, PCDDs, PCDFs for humans and wildlife.

Berg

Birnbaum

Bosveld

et al. 1998

Environ Health Perspect

2,935

975

View full text Add to dashboard Cite

“…These include partial agonists, such as 6-methy1-1,3,8-trichlorodibenzo-p-dioxin and a-naphthoflavone (Blank et al 1987;Astroff et al 1988;Merchant et al 1992;Santostefano et al 1992), and antagonists, including several substituted flavones (Lu et al 1995;Reiners et al 1998;Ciolino et al 1999;Henry et al 1999) and di-artha substituted polychlorinated biphenyls (PCBs) (Biegel et al 1989;Aarts et al 1995). In some instances AHR binding affinities and/or response inhibition IC50s were determined, but intrinsic efficacies of these ligands were not considered.…”

Section: Levels Of This Enzyme May Be Quantified By Immunoassay or Bymentioning

confidence: 99%

Mechanisms of action for aryl hydrocarbon receptor ligands in the PLHC-1 cell line

Hestermann¹

1999

View full text Add to dashboard Cite

“…Cotreatment of C57BL/6 B6 mice with PCB-153 and TCDD showed that PCB-153 partially antagonized TCDD-mediated immunotoxicity in various assays (Biegel et al, 1989). Individual congeners were also assessed for their immunotoxicity in AhR-responsive or AhR-non-responsive mouse models.…”

Section: Pcb Congenersmentioning

confidence: 99%

Polychlorinated Biphenyls and Polybrominated Biphenyls

Agudo

Aronson²,

Bonefeld-Jörgensen³

et al. 2008

Organic Pollutants

View full text Add to dashboard Cite

initiated a programme on the evaluation of the carcinogenic risk of chemicals to humans involving the production of critically evaluated monographs on individual chemicals. The programme was subsequently expanded to include evaluations of carcinogenic risks associated with exposures to complex mixtures, lifestyle factors and biological and physical agents, as well as those in specific occupations. The objective of the programme is to elaborate and publish in the form of monographs critical reviews of data on carcinogenicity for agents to which humans are known to be exposed and on specific exposure situations; to evaluate these data in terms of human risk with the help of international working groups of experts in carcinogenesis and related fields; and to indicate where additional research efforts are needed. The lists of IARC evaluations are regularly updated and are available on the Internet at http:// monographs.iarc.fr/.This programme has been supported since 1982 by Cooperative Agreement U01 CA33193 with the United States National Cancer Institute, Department of Health and Human Services. Additional support has been provided since 1986 by the European Commission Directorate-General for Employment, Social Affairs, and Inclusion, initially by the Unit of Health, Safety and Hygiene at Work, and since 2014 by the European Union Programme for Employment and Social Innovation "EaSI" (2014-2020) The International Agency for Research on Cancer welcomes requests for permission to reproduce or translate its publications, in part or in full. Requests for permission to reproduce or translate IARC publications -whether for sale or for non-commercial distribution -should be addressed to the IARC Communications Group at: publications@iarc.fr.The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the Secretariat of the World Health Organization concerning the legal status of any country, territory, city, or area or of its authorities, or concerning the delimitation of its frontiers or boundaries.The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.The IARC Monographs Working Group alone is responsible for the views expressed in this publication. IARC Library Cataloguing in Publication Data NOTE TO THE READERThe term 'carcinogenic risk' in the IARC Monographs series is taken to mean that an agent is capable of causing cancer. The Monographs evaluate cancer hazards, despite the historical presence of the word 'risks' in the title.Inclusion of an agent in the Monographs does not imply that it is a carcinogen, only that the published data have been examined. Equally, the fact that an agent has not yet been evaluated in a Monograph does not mean that...

show abstract

2,2′,4,4′,5,5′-Hexachlorobiphenyl as a 2,3,7,8-tetrachlorodibenzo-p-dioxin antagonist in C57BL6J mice

Cited by 102 publications

References 33 publications

Toxic equivalency factors (TEFs) for PCBs, PCDDs, PCDFs for humans and wildlife.

Toxic equivalency factors (TEFs) for PCBs, PCDDs, PCDFs for humans and wildlife.

Mechanisms of action for aryl hydrocarbon receptor ligands in the PLHC-1 cell line

Polychlorinated Biphenyls and Polybrominated Biphenyls

Contact Info

Product

Resources

About